ArticleHuman vaccines & immunotherapeutics2016
Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma.Bone research · 2024Article
- Reprogramming natural killer cells for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.Frontiers in cell and developmental biology · 2024Review
- Chimeric antigen receptor engineered natural killer cells for cancer therapy.Experimental hematology & oncology · 2023Review
- Article
- Current Understanding of Flavonoids in Cancer Therapy and Prevention.Metabolites · 2023Review
- Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.International journal of molecular sciences · 2023Article
- Harnessing natural killer cells to develop next-generation cellular immunotherapy.Chronic diseases and translational medicine · 2022Review
- Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment.International journal of molecular sciences · 2022Review
- Tumor microenvironment: barrier or opportunity towards effective cancer therapy.Journal of biomedical science · 2022Review
- Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells.Journal for immunotherapy of cancer · 2022Review
- Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.Cancer immunology, immunotherapy : CII · 2021Review
- Review
- Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.British journal of haematology · 2021Review
- From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.Frontiers in oncology · 2021Review
- CAR-NK Cells: From Natural Basis to Design for Kill.Frontiers in immunology · 2021Review
- Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.Cancer discovery · 2021Review
- Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells.Pharmaceutics · 2020Review
- Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.Blood science (Baltimore, Md.) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cell immunotherapies that target solid tumors require NK cells in the proper place, at the right time, with optimal function and a susceptible target cell. Basic research and clinical correlative studies have provided evidence, for certain malignancies, that intratumoral NK cells delay tumor progression. Whether NK cells exert anti-tumor effects for solid tumors is determined by a number of factors including homing and activating receptor expression by NK cells themselves and the sensitivity of tumor cells to be targets of NK cell cytolysis, which depends on the chemokine and NK cell-inhibitory and activating receptor ligand expression by tumor cells. Chemotherapeutic agents that increase NK cell-activating receptor ligands on tumor cells have been clinically promising as well as ectopic gene expression in NK cells with factors that overcome the suppressive mechanisms of the tumor microenvironment (TME). Identifying agents that decrease myeloid-derived suppressor cells (MDSC) or T regulatory (Treg) cell frequencies or function would be important to co-administer with adoptively transferred NK cells to ameliorate immunosuppressive TMEs. Thus, studies indicate that critical factors for NK cell immunotherapies targeting the TMEs are: being in the right place at the right time, with resilience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.